Exelixis, Inc.

818 articles about Exelixis, Inc.

• Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors

  5/7/2023

  Exelixis, Inc. announced that Lance Willsey, M.D. has informed the Board of Directors of his decision to resign from the Board, effective immediately.

• Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate

  5/4/2023

  Adagene Inc. announced achievement of a milestone in its ongoing collaboration with Exelixis for development of novel masked antibody-drug conjugate candidates leveraging Adagene’s proprietary SAFEbody precision masking technology.

• Exelixis to Present at the BofA Securities 2023 Healthcare Conference on May 10, 2023

  5/3/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 at 1:40 p.m. ET / 10:40 a.m. PT.

• Exelixis to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023

  4/25/2023

  Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close.

• Exelixis Advances Board Refreshment Plan

  4/13/2023

  Exelixis, Inc. announced that Carl Feldbaum, Esq. and Vincent Marchesi, M.D., Ph.D., two long-standing and valued members of the Board of Directors, will not stand for re-election at the Company’s 2023 Annual Meeting of Stockholders.

• 

  Hedge Fund Wages Proxy Battle with Exelixis Over R&D

  4/6/2023

  Farallon Capital Management is waging a proxy battle with Exelixis over R&D spending. The hedge fund issued a letter to the company’s board of directors on Wednesday.

• Farallon Issues Letter to Exelixis Board of Directors Outlining Case for Change

  4/5/2023

  Funds managed by Farallon Capital Management L.L.C. own approximately 7.2% of the outstanding shares of Exelixis, Inc., making it the Company’s largest active shareholder.

• Exelixis Announces $550 Million Share Repurchase Program

  3/20/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repurchase of up to $550 million of the company’s common stock before the end of 2023.

• Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit

  3/13/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, March 16, 2023 at 10:00 a.m. ET / 8:00 a.m. MT / 7:00 a.m. PT.

• 

  Roche, Exelixis Suffer Another Late-Stage Cancer Combo Failure

  3/3/2023

  Phase III data showed the combination of Roche’s Tecentriq and Exelixis’ Cabometyx fell short of its primary endpoint in renal cell carcinoma.

• Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer

  3/2/2023

  Exelixis, Inc. announced that the phase 3 CONTACT-03 study did not meet its primary endpoint of progression-free survival.

• Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March

  2/28/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in March.

• Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

  2/13/2023

  Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced three-year (36.5 months minimum; 44.0 months median) follow-up results from the Phase 3 CheckMate -9ER trial, demonstrating sustained survival and response rate benefits with the combination of Opdivo® (nivolumab) and CABOMETYX® (cabozantinib) versus sunitinib in the first-line treatment of advanced renal cell carcinoma (RCC).

• Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors

  2/13/2023

  Exelixis, Inc. (Nasdaq: EXEL) and Sairopa B.V. (Sairopa) today announced that the U.S. Food and Drug Administration (FDA) has cleared Sairopa’s Investigational New Drug (IND) Application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors.

• Exelixis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  2/7/2023

  Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and full year of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

• Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February

  2/2/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February.

• Exelixis to Release Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

  1/24/2023

  Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close.

• Exelixis Announces Update on Patent Litigation with MSN Laboratories

  1/19/2023

  Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to the cabozantinib compound patent (U.S. 7,579,473).

• Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023

  1/8/2023

  Exelixis, Inc. announced its preliminary unaudited financial results for the fourth quarter and full year 2022, provided financial guidance for full year 2023, and delivered an update on its business.

• Exelixis to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023

  1/3/2023

  Exelixis, Inc. announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15pm ET / 5:15pm PT.